Adamas Pharma (ADMS)

8.220 +0.000 (+0.00%)
Closed USD Disclaimer

ADMS Financial Summary

For the nine months ended 30 September 2021, AdamasPharmaceuticals Inc revenues increased 26% to $67.2M. Netloss increased 14% to $44.4M. Revenues reflect Productsales increase of 23% to $63.1M, Royalty revenue increaseof 99% to $4.1M. Higher net loss reflects Other General andAdministrative. increase of 16% to $80.3M (expense),Stock-based Compensation in General increase of 16% to$5.2M (expense).
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
ADMS
Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
Total Revenue
Net Income
Title
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Total Revenue 25.90 21.97 19.31 21.01
Gross Profit 25.32 21.45 18.93 20.41
Operating Income -5.64 -9.15 -9.53 -14.98
Net Income -19.52 -12.34 -12.57 -18.27
Clear All
0Selected
Please try another search
ADMS
Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
Total Assets
Total Liabilities
Title
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Total Assets 143.98 150.64 169.25 120.03
Total Liabilities 165.58 154.68 163.31 170
Total Equity -21.61 -4.03 5.94 -49.98
Clear All
0Selected
Please try another search
ADMS
Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow -153.06%
Cash
Net Change in Cash
Title
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Cash From Operating Activities -36.49 -30.24 -21.06 -50.71
Cash From Investing Activities -22.07 -19.06 7.79 54.94
Cash From Financing Activities 65.52 66.44 66.44 1.65
Net Change in Cash 6.96 17.14 53.17 5.89
Clear All
0Selected
Please try another search

* In Millions of (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.